Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6681366 | 0.92 | MAPT (0.56) | MAPTLMNATHRBRXFP1TP53 | |
| SCHEMBL6684559 | 0.91 | MAPT (0.53) | MAPTLMNATHRBRXFP1TP53 | |
| SCHEMBL6684875 | 0.90 | MAPT (0.49) | MAPTLMNATHRBRXFP1TP53 | |
| SCHEMBL6678534 | 0.89 | MAPT (0.48) | MAPTLMNATHRBRXFP1TP53 | |
| SCHEMBL6683273 | 0.89 | MAPT (0.49) | MAPTLMNATHRBRXFP1TP53 | |
| SCHEMBL6668041 | 0.89 | MAPT (0.51) | MAPTLMNARXFP1TP53RAB9A | |
| SCHEMBL6680500 | 0.88 | MAPT (0.47) | MAPTLMNATHRBRXFP1TP53 | |
| SCHEMBL6680173 | 0.83 | ALDH1A1 (0.53) | MAPTLMNATHRBRXFP1TP53 | |
| SCHEMBL6678821 | 0.83 | MAPT (0.53) | MAPTLMNATHRBRXFP1TP53 | |
| SCHEMBL6831840 | 0.81 | TP53 (0.42) | MAPTLMNATHRBTP53CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014388-A1 | 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP26, MMP9 | MAPT 2365/4885LMNA 2566/4885THRB 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.